Morepen files first US drug application, eyes generic diabetes market

The Hindu Business Line - Sep 28, 2026

Morepen’s first US submission targets a late-stage entry into the global diabetes therapeutics market, leveraging a DPP-4 inhibitor with potential competitive timelines and regulatory milestones

Read full article
More News
Copyright © 2015 - 2026 The Financial Capital.

All Rights Reserved.

Subscribe Now!

About Us

The Financial Capital is your independent source for finance information and advice. We provide insights and offer advice from financial experts so you can make the best decisions.